-

01:44:09 AM

SLRX Stock News

SLRX - Salarius Pharmaceuticals Inc

07/13/21 7:33 AM

Nasdaq : SLRX

Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers,

RHEA-AI

neutral

07/09/21 7:33 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer,

RHEA-AI

neutral

06/17/21 8:03 AM

Nasdaq : SLRX

conferences

REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage

RHEA-AI

neutral

06/15/21 7:30 AM

Nasdaq : SLRX

clinical trial

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage

RHEA-AI

neutral

06/10/21 1:30 PM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage

RHEA-AI

neutral

06/07/21 7:35 AM

Nasdaq : SLRX

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial Initial drug activity observed in both relapsed/refractory Ewing sarcoma and AST trials Advanced FET-rearranged sarcoma patients in AST

RHEA-AI

neutral

05/19/21 5:01 PM

Nasdaq : SLRX

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials Presentations include full data from dose-escalation stage of Phase 1/2 clinical trial evaluating seclidemstat in Ewing sarcoma and preliminary data from ongoing AST trial HOUSTON, May

RHEA-AI

neutral

05/12/21 4:05 PM

Nasdaq : SLRX

earnings

Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights

RHEA-AI

neutral

05/05/21 7:05 AM

Nasdaq : SLRX

conferencesearnings

Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers,

RHEA-AI

neutral

04/29/21 7:30 AM

Nasdaq : SLRX

Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted for

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

SLRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitesalariuspharma.com
CeoDavid Arthur
Security nameSalarius Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees8
Tags
- Health Technology
- Pharmaceuticals: Other
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2450 Holcombe Blvd Ste J-608
StateTexas
CityHouston
Zip77021-2041
CountryUS
Phone13467720346

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Ewing sarcoma has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).